Abstract
Living cell could be considered the most sophisticated anti-entropy machinery born in the heart of the strong and ferocious pro-entropy environment of the primordial ocean full of boiling and salty water, some thirty-eight hundred million years ago on this planet. Evolution of prokaryotes with a simple cell membrane to eukaryotes and later on multi-cellular organisms, has necessitated the birth and evolution of a protective microenvironment, which could shield and secure evolution of living organisms by its sophisticated anti-entropy components, including its vasculature, immune modulating and growth promoting genes and molecules. It is easy to conceive that an acquired or genetically inherited defect in each of the protective layers built into the matrix of microenvironment, could potentially open the gate on catastrophic events including neoplastic transformation. Massive interconnectivity of cells and microenvironment, would also allow defects originating in cells to spill into adjacent microenvironment. This, in turn would change an anti-entropy microenvironment into a pro-entropy one, perpetuating a vicious cycle. As such, our future cancer therapeutics should be based on deep understanding of these fundamental principles and their perturbations. Such understanding, would open the way on design of future cancer therapeutics.
Keywords
Cancer, Microenvironment, Entropy, Programmable nano-machines, Inflammation, Telomere
Introduction
In the last several decades, literature has got flooded with publications addressing the significance of microenvironment [1] in the evolution and perpetuation of neoplastic transformation [2]. Cells comprising the microenvironment ranging from fibroblasts to immune cells and their derived growth and immunomodulatory factors have been elucidated to a significant degree [3]. Thalidomide, the first generation IMiD [4] was perhaps the starting point in addressing the growth and proliferation signals originating in microenvironment of multiple myeloma [5]. Such inhibition, opened a new chapter in treatment of multiple myeloma many years ago. Programmed Death-1 antagonists [6] unleashing the tumor destructive capability of immune cells residing in the microenvironment, present another example in the fairly recent cancer therapeutic literature in this regard. Lack of universal success by using these agents in different types of neoplastic disorders, denotes a much deeper level of complexity in the interaction of microenvironment and cancer [7], that has yet not been tapped on. As such, one might reasonably conclude that there is no black and white relationship between microenvironment and cancer, and rather there are different grades of grey. To address these variations and uncertainties, one needs to refer to the most fundamental law that determines the fine tuning and creation of living organism, namely the second law of thermodynamics [8]. The deep dissection of the interplay of the second law of thermodynamics and living cell and its breakdown [9], would enable us to come up with a model that could potentially describe these variations and generate a blueprint to address different dominant scenarios in different malignancies.
Entropy, Microenvironment and Carcinogenesis
Microenvironment, could perhaps be best defined as a barrier between the pro-entropy environment and the living cell [10]. Some thirty-eight hundred million years ago, when the first prokaryote was born in the boiling and salty water of the primordial ocean [11], the only barrier between the genome and the pro-entropy environment was the cell membrane.
With the birth of eukaryotes [12] and later on multi-cellular organisms [13], more sophisticated barriers, such as nuclear membrane [14] and transcellular pumps and transmembrane receptors came into existence [15].
These barriers, pumps and receptors [16] acted as guardians of the cellular genome, helped with extrusion of noxious agents and transfer of life sustaining elements to the living cell.
The history of evolution of life on this planet could be best defined as a constant tug of war between the pro-entropy environment [17] and universe on one hand and the anti-entropy living cells [18], which have become able to secure the lowest amount of cellular networks entropy [19] and maximum free energy [20], on the other hand. The major means of such achievement, has been the buildup of more sophisticated barriers, as well as growth and survival loops.
Along the same line, microenvironment has come into existence to generate a safe and protective bed for living cells and tissues. However, numerous pro-entropy forces and elements are constantly attacking the cell and the microenvironment.
Consequently, both the cell and the microenvironment should be able to constantly antagonize such pro-entropy elements and repair their ensuing damage [21]. Inflammation and inflammatory signals [22] could be considered the most immediate and lethal agents, threating the integrity of the genome. Radiation and environmental toxins and chemicals are constantly damaging both the cell and the microenvironment. Simultaneously, passage of time along the thermodynamic arrow would independently lead to increase in entropy. The living organism is loaded with protective mechanisms and sensors of damage at all levels, ranging from genome to epigenome and micro-RNA network all the way to membrane and microenvironment [23].
As one example, mid-life examination of cells of different human tissues has revealed numerous mutations aiming at pro-inflammatory damaging signals [24]. Such mutations, which have come into existence to protect the cell, would prove carcinogenic during the latter years of human life. Telomeres would also alert the cell [25], through their shortening along the axis of time following numerous replications and activate apoptosis before catastrophic mutations exert their malignant transformation property.
The response of the non-cellular compartment of microenvironment to the pro-entropy and damaging environmental agents [26], is through their physical modifications, such as stiffening and architectural distortions [27]. Clearly such physical distortions, which translate into less freedom of motion and plasticity and hence increased entropy would diffuse into the surrounding cells [28].
Consequently, the affected cells' genetic programming get affected at numerous levels, including genome, epigenome, micro-RNA and
protein-protein interactions with the end result of higher cellular network entropy (Figure 1). The answer to the big question of where neoplastic transformation starts [31], has to do with speed and pace of damage of microenvironment and surrounding cells, as well as their speed of recovery and the built-in interdependency which is a function of parallel evolution of these compartments. As such, all possibilities are viable [32]. Consequently, the damaged microenvironment with higher entropy could lead to increase in cellular network entropy of its comprising cells and adjacent cells outside the microenvironment and generate a reverberating vicious cycle.
Figure 1: Microenvironment. A) Tumor microenvironment: More rigidity, less plasticity, higher entropy, enriched with S-S double bonds of fibulin [29]; B) Normal Microenvironment: Less rigidity, more plasticity, lower entropy, infrequent or nil S-S double bonds of fibulin [30].
As one example, in glioblastoma multiform alternate splicing of EFEMP1 RNA [33], would inhibit the formation of ETSP, EFEMP1 tumor suppressor and promote the formation of the oncogenic version of EFEMP1, with its downstream growth and promotion pathway factors and its associated MMP (matrix metallo protease) [34], which would spill into its adjacent microenvironment. EFEMP1, would lead to generation of disulfide bonds of certain matrix proteins, such as fibulins [35]. This would lead to their stiffness and lack of freedom of motion, plasticity and remodeling. This is the proto-type example of high entropy microenvironment.
MMPs, through digestion of matrix proteins would open the way for metastatic spread of malignant cells and for the promotion of mutations and increase in chromosomal/genetic instability and intra-tumor heterogeneity [36].
The combination of simultaneous and irreversible damage to microenvironment and cellular compartment is another theoretical and potential possibility [37].
The surprising and dramatic response of multiple myeloma patients to agents that interfere with growth and proliferation pathways originating in microenvironment [38], is highly supportive of the damaged microenvironment, as the central pathology of multiple myeloma. By the same token, lack of response to such agents in patients with carcinoma of lung, is quite supportive of irreversible cellular damage, as the central pathology in such patients [39]. On occasion, synergistic positive response to combination of treatment against microenvironment and malignant cell, such as certain subtypes of non-hodgkin lymphoma, is supportive of dual, irreversible damage to microenvironment and lymphocyte [40].
Conclusion
Deep understanding of the interplay of microenvironment and neoplastic cell and the dominant role played by each, is in need of dissection of the central role played by the second law of thermodynamics, in initiation and evolution of living organism and the evolutionary dynamics of these two compartments [41].
Evolution of microenvironment as a barrier between the pro entropy environment and the living cell [42], as well as a balanced growth and proliferation promoting ground of the cells embedded in it, plays a central role in this regard.
It is only when the entropy of one or both of these two compartments increases inappropriately and irreversibly, that neoplastic transformation arises [43]. Each neoplastic disease has to be dissected accordingly and customized treatment generated for that specific scenario. As such, the enemy, which is the pathologic and irreversible increase in entropy [44], could come into existence in the microenvironment and expand into adjacent cells, vice-a-versa, or a combination of both.
Development of the future generation of cancer therapeutics, necessitates delicate measurement of systems entropy at microenvironment and cellular levels [45].
It is my hope that programmable nano-machines [46] would get programmed toward decreasing systems entropy in a customized fashion and get delivered to the culprit zone to achieve this goal. By that time, chemo, immune, and radiation therapy would join history (Figure 2).
Figure 2: Programmable nanomachines (adopted from Afrasiabi 2021, [47]). Three different mechanisms, through which programmable nan-machines could decrease systems network entropy in microenvironment and cancer cell. Type A: Nano-machine could deliver the electrostatic force of interest to take the value towards normalcy [48]; Type B: Nano-machine could deliver the missing micro-RNA. Following identification of cancer cell of interest by sensor [49]; Type C: Nano-machine could modify the genetic code of interest. Following identification of cancer cell of interest by sensor [50]. Propeller moves nano-machine in the microenvironment or among tumor cells in tumor mass. Sensor identifies increased entropy, through numerous mechanisms including a ligand specific to a receptor on cancer cell of interest, or rigid microenvironment.
References
2. Gouirand V, Guillaumond F, Vasseur S. Influence of the tumor microenvironment on cancer cells metabolic reprogramming. Frontiers in Oncology. 2018 Apr 19;8:117.
3. Hirata E, Sahai E. Tumor microenvironment and differential responses to therapy. Cold Spring Harbor Perspectives in Medicine. 2017 Jul 1;7(7):a026781.
4. García-Sanz R. Thalidomide in multiple myeloma. Expert Opinion on Pharmacotherapy. 2006 Feb 1;7(2):195-213.
5. de Jong MM, Kellermayer Z, Papazian N, Tahri S, Hofste op Bruinink D, Hoogenboezem R, et al. The multiple myeloma microenvironment is defined by an inflammatory stromal cell landscape. Nature Immunology. 2021 Jun;22(6):769-80.
6. Jiang Y, Chen M, Nie H, Yuan Y. PD-1 and PD-L1 in cancer immunotherapy: clinical implications and future considerations. Human Vaccines & Immunotherapeutics. 2019 May 4;15(5):1111-22.
7. Makuku R, Khalili N, Razi S, Keshavarz-Fathi M, Rezaei N. Current and future perspectives of PD-1/PDL-1 blockade in cancer immunotherapy. Journal of Immunology Research. 2021 Feb 22;2021.
8. Trevors JT, Saier Jr MH. Thermodynamic perspectives on genetic instructions, the laws of biology and diseased states. Comptes Rendus Biologies. 2011 Jan 1;334(1):1-5.
9. Lane N, Martin W. The energetics of genome complexity. Nature. 2010 Oct;467(7318):929-34.
10. Davies PC, Rieper E, Tuszynski JA. Self-organization and entropy reduction in a living cell. Biosystems. 2013 Jan 1;111(1):1-0.
11. Stanier RY, Van Niel CB. The concept of a bacterium. Archiv für Mikrobiologie. 1962 Mar;42(1):17-35.
12. Leander BS. Predatory protists. Current Biology. 2020 May 18;30(10):R510-6.
13. Parfrey LW, Lahr DJ. Multicellularity arose several times in the evolution of eukaryotes (Response to DOI 10.1002/bies. 201100187). Bioessays. 2013 Apr;35(4):339-47.
14. Hetzer MW. The nuclear envelope. Cold Spring Harbor Perspectives in Biology. 2010 Mar 1;2(3):a000539.
15. Cuatrecasas P. Membrane receptors. Annual review of biochemistry. 1974 Jul;43(1):169-214.
16. Alberts B, Johnson A, Lewis J, Raff M, Roberts K, Walter P. General principles of cell communication. InMolecular Biology of the Cell. 4th edition 2002. Garland Science.
17. Marenduzzo D, Micheletti C, Cook PR. Entropy-driven genome organization. Biophysical Journal. 2006 May 15;90(10):3712-21.
18. Peterson J. Understanding the thermodynamics of biological order. The American Biology Teacher. 2012 Jan;74(1):22-4.
19. Wehrl A. General properties of entropy. Reviews of Modern Physics. 1978 Apr 1;50(2):221.
20. Wohl I, Sherman E. ATP-dependent diffusion entropy and homogeneity in living cells. Entropy. 2019 Oct;21(10):962.
21. Fittall MW, Van Loo P. Translating insights into tumor evolution to clinical practice: promises and challenges. Genome Medicine. 2019 Dec;11(1):1-4.
22. Kiraly O, Gong G, Olipitz W, Muthupalani S, Engelward BP. Inflammation-induced cell proliferation potentiates DNA damage-induced mutations in vivo. PLoS Genetics. 2015 Feb 3;11(2):e1004901.
23. Jaenisch R, Bird A. Epigenetic regulation of gene expression: how the genome integrates intrinsic and environmental signals. Nature Genetics. 2003 Mar;33(3):245-54.
24. Kay J, Thadhani E, Samson L, Engelward B. Inflammation-induced DNA damage, mutations and cancer. DNA Repair. 2019 Nov 1;83:102673.
25. López-Otín C, Blasco MA, Partridge L, Serrano M, Kroemer G. The hallmarks of aging. Cell. 2013 Jun 6;153(6):1194-217.
26. Chen L, Deng H, Cui H, Fang J, Zuo Z, Deng J, et al. Inflammatory responses and inflammation-associated diseases in organs. Oncotarget. 2018 Jan 23;9(6):7204.
27. Miller MA, Zachary JF. Mechanisms and morphology of cellular injury, adaptation, and death. Pathologic Basis of Veterinary Disease. 2017:2.
28. Tarabichi M, Antoniou A, Saiselet M, Pita JM, Andry G, Dumont JE, et al. Systems biology of cancer: entropy, disorder, and selection-driven evolution to independence, invasion and “swarm intelligence”. Cancer and Metastasis Reviews. 2013 Dec;32(3):403-21.
29. Nassar D, Blanpain C. Cancer stem cells: basic concepts and therapeutic implications. Annual Review of Pathology: Mechanisms of Disease. 2016 May 23;11:47-76.
30. Shenoy S. Cell plasticity in cancer: A complex interplay of genetic, epigenetic mechanisms and tumor micro-environment. Surgical Oncology. 2020 Sep 1;34:154-62.
31. Zheng X, Yu C, Xu M. Linking tumor microenvironment to plasticity of cancer stem cells: mechanisms and application in cancer therapy. Frontiers in Oncology. 2021 Jun 28;11:2552.
32. Raghavan S, Winter PS, Navia AW, Williams HL, DenAdel A, Lowder KE, et al. Microenvironment drives cell state, plasticity, and drug response in pancreatic cancer. Cell. 2021 Dec 9;184(25):6119-37.
33. Hu Y, Pioli PD, Siegel E, Zhang Q, Nelson J, Chaturbedi A, et al. EFEMP1 suppresses malignant glioma growth and exerts its action within the tumor extracellular compartment. Molecular Cancer. 2011 Dec;10(1):1-2.
34. Klein T, Bischoff R. Physiology and pathophysiology of matrix metalloproteases. Amino Acids. 2011 Jul;41(2):271-90.
35. De Vega S, Iwamoto T, Yamada Y. Fibulins: multiple roles in matrix structures and tissue functions. Cellular and Molecular Life Sciences. 2009 Jun;66(11):1890-902.
36. Vargas-Rondón N, Villegas VE, Rondón-Lagos M. The role of chromosomal instability in cancer and therapeutic responses. Cancers. 2017 Dec 28;10(1):4.
37. Cinat D, Coppes RP, Barazzuol L. DNA Damage-Induced Inflammatory Microenvironment and Adult Stem Cell Response. Frontiers in Cell and Developmental Biology. 2021:2497.
38. Kawano Y, Moschetta M, Manier S, Glavey S, Görgün GT, Roccaro AM, et al. Targeting the bone marrow microenvironment in multiple myeloma. Immunological Reviews. 2015 Jan;263(1):160-72.
39. Wang S, Li Z, Gao S. Key regulators of sensitivity to immunomodulatory drugs in cancer treatment. Biomarker Research. 2021 Dec;9(1):1-0.
40. Anagnostou T, Ansell SM. Immunomodulators in lymphoma. Current Treatment Options in Oncology. 2020 Apr;21(4):1-3.
41. Van Ness HC. Understanding thermodynamics. Courier Corporation; 1983.
42. Hanselmann RG, Welter C. Origin of cancer: an information, energy, and matter disease. Frontiers in Cell and Developmental Biology. 2016 Nov 17;4:121.
43. Dumont JE, Dremier S, Pirson I, Maenhaut C. Cross signaling, cell specificity, and physiology. American Journal of Physiology-Cell Physiology. 2002 Jul 1;283(1):C2-8.
44. Cheng F, Liu C, Shen B, Zhao Z. Investigating cellular network heterogeneity and modularity in cancer: a network entropy and unbalanced motif approach. BMC Systems Biology. 2016 Aug;10(3):301-11.
45. Park Y, Lim S, Nam JW, Kim S. Measuring intratumor heterogeneity by network entropy using RNA-seq data. Scientific Reports. 2016 Nov 24;6(1):1-2.
46. Chen YJ, Dalchau N, Srinivas N, Phillips A, Cardelli L, Soloveichik D, et al. Programmable chemical controllers made from DNA. Nature Nanotechnology. 2013 Oct;8(10):755-62.
47. Afrasiabi K. Entropy and cancer: The future of cancer Therapeutics. J Cancer Biol 2021; 2(3): 62-67.
48. Haley NE, Ouldridge TE, Mullor Ruiz I, Geraldini A, Louis AA, Bath J, et al. Design of hidden thermodynamic driving for non-equilibrium systems via mismatch elimination during DNA strand displacement. Nature Communications. 2020 May 22;11(1):1-1.
49. Wei T, Cheng Q, Min YL, Olson EN, Siegwart DJ. Systemic nanoparticle delivery of CRISPR-Cas9 ribonucleoproteins for effective tissue specific genome editing. Nature Communications. 2020 Jun 26;11(1):1-2.
50. Dynan WS, Takeda Y, Li S. Modifying the function of DNA repair nanomachines for therapeutic benefit. Nanomedicine: Nanotechnology, Biology and Medicine. 2006 Jun 1;2(2):74-81.

